Parameters | Number of cases | METTL3 expression | P Value |
---|
Low | High |
---|
All cases | 180 | 97 | 83 | Â |
Age(years) |
 <65 | 76 | 43 | 33 | 0.536 |
 ≥65 | 104 | 54 | 50 |  |
Gender |
 Male | 141 | 73 | 68 | 0.279 |
 Female | 39 | 24 | 15 |  |
TNM stage |
 pTa-pT1 | 116 | 64 | 52 | 0.642 |
 pT2-pT4 | 64 | 33 | 31 |  |
Histological grade |
 Low | 78 | 50 | 28 | 0.016a |
 High | 102 | 47 | 55 |  |
Tumor size(cm) |
 <3 | 114 | 66 | 48 | 0.156 |
 ≥3 | 66 | 31 | 35 |  |
- aStatistically significant, P<0.05
- Notes: The total METTL3 immunostaining score was calculated as the sum of the score for the proportion of positively stained tumor cells (PP) and the score for staining intensity (SI) given by two pathologists blinded to the clinical parameters. PP was scored into four categories: 0 (< 5%, negative), 1 (5–25%, sporadic), 2 (25–50%, focal), 3 (> 51%, diffuse) and SI was scored on a scale of 0 to 3 (0, negative staining; 1, weak staining; 2, moderate staining; 3, strong staining). The final staining score was calculated by multiplying SI and PP score, resulting in a score value ranging from 0 to 9. The positive level of IHC staining was scored by two urologists and patients with different scores were divided into low- (0–3) and high-staining (4–9) groups